FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3090535413> ?p ?o ?g. }

• W3090535413 endingPage "1444" @default.
• W3090535413 startingPage "1433" @default.
• W3090535413 abstract "In the Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG Outcome), empagliflozin, in addition to standard of care, significantly reduced risk of cardiovascular death by 38%, hospitalization for heart failure by 35%, and incident or worsening nephropathy by 39% compared with placebo in patients with type 2 diabetes and established cardiovascular disease. Using EMPA-REG Outcome data, we assessed whether the Kidney Disease Improving Global Outcomes (KDIGO) CKD classification had an influence on the treatment effect of empagliflozin.Patients with type 2 diabetes, established atherosclerotic cardiovascular disease, and eGFR≥30 ml/min per 1.73 m2 at screening were randomized to receive empagliflozin 10 mg, empagliflozin 25 mg, or placebo once daily in addition to standard of care. Post hoc, we analyzed cardiovascular and kidney outcomes, and safety, using the two-dimensional KDIGO classification framework.Of 6952 patients with baseline eGFR and urinary albumin-creatinine ratio values, 47%, 29%, 15%, and 8% were classified into low, moderately increased, high, and very high KDIGO risk categories, respectively. Empagliflozin showed consistent risk reductions across KDIGO categories for cardiovascular outcomes (P values for treatment by subgroup interactions ranged from 0.26 to 0.85) and kidney outcomes (P values for treatment by subgroup interactions ranged from 0.16 to 0.60). In all KDIGO risk categories, placebo and empagliflozin had similar adverse event rates, the notable exception being genital infection events, which were more common with empagliflozin for each category.The observed effects of empagliflozin versus placebo on cardiovascular and kidney outcomes were consistent across the KDIGO risk categories, indicating that the effect of treatment benefit of empagliflozin was unaffected by baseline CKD status.EMPA-REG OUTCOME, NCT01131676." @default.
• W3090535413 created "2020-10-08" @default.
• W3090535413 creator A5007480850 @default.
• W3090535413 creator A5027520502 @default.
• W3090535413 creator A5033368647 @default.
• W3090535413 creator A5034066967 @default.
• W3090535413 creator A5041848843 @default.
• W3090535413 creator A5046130400 @default.
• W3090535413 creator A5067356779 @default.
• W3090535413 creator A5069865054 @default.
• W3090535413 date "2020-09-29" @default.
• W3090535413 modified "2023-10-17" @default.
• W3090535413 title "Empagliflozin and Cardiovascular and Kidney Outcomes across KDIGO Risk Categories" @default.
• W3090535413 cites W1982967737 @default.
• W3090535413 cites W1997042641 @default.
• W3090535413 cites W2012282857 @default.
• W3090535413 cites W2106610064 @default.
• W3090535413 cites W2120309176 @default.
• W3090535413 cites W2146264128 @default.
• W3090535413 cites W2149030597 @default.
• W3090535413 cites W2424539745 @default.
• W3090535413 cites W2430309464 @default.
• W3090535413 cites W2467227824 @default.
• W3090535413 cites W2492672367 @default.
• W3090535413 cites W2512006388 @default.
• W3090535413 cites W2552060437 @default.
• W3090535413 cites W2626446274 @default.
• W3090535413 cites W2733849831 @default.
• W3090535413 cites W2750589886 @default.
• W3090535413 cites W2756191633 @default.
• W3090535413 cites W2791929692 @default.
• W3090535413 cites W2794310633 @default.
• W3090535413 cites W2808725516 @default.
• W3090535413 cites W2897993744 @default.
• W3090535413 cites W2898388822 @default.
• W3090535413 cites W2899764361 @default.
• W3090535413 cites W2900413769 @default.
• W3090535413 cites W2939222610 @default.
• W3090535413 cites W2954659053 @default.
• W3090535413 cites W2962169757 @default.
• W3090535413 cites W2970412630 @default.
• W3090535413 cites W2971414122 @default.
• W3090535413 cites W2974260792 @default.
• W3090535413 cites W2980268988 @default.
• W3090535413 cites W3005350465 @default.
• W3090535413 cites W4242364069 @default.
• W3090535413 doi "https://doi.org/10.2215/cjn.14901219" @default.
• W3090535413 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7536760" @default.
• W3090535413 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32994159" @default.
• W3090535413 hasPublicationYear "2020" @default.
• W3090535413 type Work @default.
• W3090535413 sameAs 3090535413 @default.
• W3090535413 citedByCount "35" @default.
• W3090535413 countsByYear W30905354132020 @default.
• W3090535413 countsByYear W30905354132021 @default.
• W3090535413 countsByYear W30905354132022 @default.
• W3090535413 countsByYear W30905354132023 @default.
• W3090535413 crossrefType "journal-article" @default.
• W3090535413 hasAuthorship W3090535413A5007480850 @default.
• W3090535413 hasAuthorship W3090535413A5027520502 @default.
• W3090535413 hasAuthorship W3090535413A5033368647 @default.
• W3090535413 hasAuthorship W3090535413A5034066967 @default.
• W3090535413 hasAuthorship W3090535413A5041848843 @default.
• W3090535413 hasAuthorship W3090535413A5046130400 @default.
• W3090535413 hasAuthorship W3090535413A5067356779 @default.
• W3090535413 hasAuthorship W3090535413A5069865054 @default.
• W3090535413 hasBestOaLocation W30905354131 @default.
• W3090535413 hasConcept C126322002 @default.
• W3090535413 hasConcept C134018914 @default.
• W3090535413 hasConcept C142724271 @default.
• W3090535413 hasConcept C177713679 @default.
• W3090535413 hasConcept C204787440 @default.
• W3090535413 hasConcept C27081682 @default.
• W3090535413 hasConcept C2775887513 @default.
• W3090535413 hasConcept C2777180221 @default.
• W3090535413 hasConcept C2778653478 @default.
• W3090535413 hasConcept C555293320 @default.
• W3090535413 hasConcept C71924100 @default.
• W3090535413 hasConceptScore W3090535413C126322002 @default.
• W3090535413 hasConceptScore W3090535413C134018914 @default.
• W3090535413 hasConceptScore W3090535413C142724271 @default.
• W3090535413 hasConceptScore W3090535413C177713679 @default.
• W3090535413 hasConceptScore W3090535413C204787440 @default.
• W3090535413 hasConceptScore W3090535413C27081682 @default.
• W3090535413 hasConceptScore W3090535413C2775887513 @default.
• W3090535413 hasConceptScore W3090535413C2777180221 @default.
• W3090535413 hasConceptScore W3090535413C2778653478 @default.
• W3090535413 hasConceptScore W3090535413C555293320 @default.
• W3090535413 hasConceptScore W3090535413C71924100 @default.
• W3090535413 hasFunder F4320306257 @default.
• W3090535413 hasFunder F4320307758 @default.
• W3090535413 hasIssue "10" @default.
• W3090535413 hasLocation W30905354131 @default.
• W3090535413 hasLocation W30905354132 @default.
• W3090535413 hasLocation W30905354133 @default.
• W3090535413 hasLocation W30905354134 @default.
• W3090535413 hasOpenAccess W3090535413 @default.
• W3090535413 hasPrimaryLocation W30905354131 @default.

• next